Market Analysis

Anthem Biosciences pops 27% on debut. However is it too expensive?

StockWaves By StockWaves 0 Min Read
Anthem Biosciences pops 27% on debut. However is it too expensive?



Robust itemizing for the biotech agency alerts investor pleasure. Valuation, although, raises eyebrows.

Share This Article
Previous Article Patel Engineering Shares Surge 1.5% on Contract Win Patel Engineering Shares Surge 1.5% on Contract Win
Next Article Fortis Healthcare Ltd — Shaping India’s Subsequent-Gen CareInsights Fortis Healthcare Ltd — Shaping India’s Subsequent-Gen CareInsights
Leave a comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Most Popular